Concepedia

Author

Berna Beverloo

Erasmus MC

Also Known As

B Beverloo, B. Berna Beverloo, B. Beverloo, Berna B. Beverloo, Berna Berna Beverloo, Berna Beverloo, Joelle Tchinda

41

Publications

990

Citations

11

H-Index

12

Concepts

All Affiliations

Erasmus MCErasmus University RotterdamHeidelberg UniversityErasmus MC - Sophia Children’s HospitalHovon
BB

About

Berna Beverloo is an author at Erasmus MC specializing in radiation oncology, hematology, and health sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

2

2

80

2

Medicine

2

2

80

3

Cell Biology

1

1

65

4

Pathology

1

1

65

5

Clinical Trials

1

1

15

Berna Beverloo

×

10

Publications

776

Citations

10

H-Index

YearCitations

Mutations in a TGF-β Ligand, TGFB3, Cause Syndromic Aortic Aneurysms and Dissections

Aida M. Bertoli‐Avella, Elisabeth Gillis, Hiroko Morisaki,

Journal of the American College of Cardiology

2015

290

Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium

C. Michel Zwaan, Carmelo Rizzari, Françoise Méchinaud,

Journal of Clinical Oncology

2013

93

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

Pieter Sonneveld, Ingo Schmidt‐Wolf, Bronno van der Holt,

Blood

2010

88

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high‐dose chemotherapy in patients with multiple myeloma

Ka Lung Wu, Berna Beverloo, Henk M. Lokhorst,

British Journal of Haematology

2007

73

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

Pieter Sonneveld, Bronno van der Holt, I G Schmidt-Wolf,

Blood

2008

66

MLL amplification in myeloid leukemias: A study of 14 cases with multiple copies of 11q23

Lucienne Michaux, Iwona Włodarska, Michel Stul,

Genes Chromosomes and Cancer

2000

65

Mutation of the mouse Rad17 gene leads to embryonic lethality and reveals a role in DNA damage‐dependent recombination

Magda Budzowska, Iris Jaspers, Jeroen Essers,

The EMBO Journal

2004

61

FIRST ANALYSIS OF HOVON-65/GMMG-HD4 RANDOMIZED PHASE III TRIAL COMPARING BORTEZOMIB, ADRIAMYCINE, DEXAMETHASONE (PAD) VS VAD AS INDUCTION TREATMENT PRIOR TO HIGH DOSE MELPHALAN (HDM) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)

Pieter Sonneveld, Bronno van der Holt, I G Schmidt-Wolf,

Haematologica

2009

15

Complex and monosomal karyotype are distinct cytogenetic entities with an adverse prognostic impact in paediatric acute myeloid leukaemia. A <scp>NOPHO</scp>‐<scp>DBH</scp>‐<scp>AML</scp> study

Ninna Bager, Kristian Juul-Dam, Julie Damgaard Sandahl,

British Journal of Haematology

2018

14

Dasatinib in Children and Adolescents with Relapsed or Refractory Leukemia: Interim Results of the CA180-018 Phase I Study from the ITCC Consortium.

C. Michel Zwaan, Carmelo Rizzari, Vincent H. J. van der Velden,

Blood

2008

11

Page 1